

# ESACT Proceedings

Volume 4

For further volumes:  
<http://www.springer.com/series/5936>

Thomas Noll  
Editor

# Cells and Culture

Proceedings of the 20th ESACT Meeting,  
Dresden, Germany, June 17–20, 2007

 Springer

*Editor*

Prof. Dr. Thomas Noll  
Universität Bielefeld  
Technische Fak.  
AG Zellkulturtechnik  
33501 Bielefeld  
Germany

ISBN 978-90-481-3418-2 e-ISBN 978-90-481-3419-9

DOI 10.1007/978-90-481-3419-9

Springer Dordrecht Heidelberg London New York

Library of Congress Control Number: 2010927813

© Springer Science+Business Media B.V. 2010

No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

# Contents

## Part I Single-Cell Analysis and Engineering

<b>Targeted Gene Knockdown Effects on Recombinant Protein Secretion in CHO Cells</b> . . . . .	3
Trissa Borgschulte, Fanny Delegrange, Christoph L. Bausch, David L. Hacker, Daniel W. Allison, Matthew V. Caple, Florian M. Wurm, and Kevin J. Kayser	
<b>RNA Silencing Suppressors Boost the Production of Recombinant Proteins and Viruses</b> . . . . .	9
Peter de Haan, Alfred Engel, Walter de Vries, Jeroen van der Velden, Gerrit-Jan van Holst, and Eddy Arnoldussen	
<b>Towards the Use of CHO Produced Recombinant Extracellular Matrix Proteins as Bioactive Elements in a 3-D Scaffold for Tissue Engineering</b> . . . . .	13
Eva-Maria Engelhardt, A. Oberbek, D. Aibibu, G. Backliwal, M. Adam, J. Hilborn, and F.M. Wurm	
<b>Transient Gene Expression in Chinese Hamster Ovary Cells at Low Temperature – The Effects of Cold-Induced Proteins and an mRNA Regulatory Element</b> . . . . .	19
Sarah Wulhfard, Stéphanie Tissot, David L. Hacker, and Florian M. Wurm	
<b>Single-Cell Approach in Influenza Vaccine Production: Apoptosis and Virus Protein Production</b> . . . . .	25
Josef Schulze-Horsel, Mareike Schulze, Yvonne Genzel, and Udo Reichl	
<b>Chondrogenic Differentiation of Human Mesenchymal Stem Cells During Multiple Subcultivation</b> . . . . .	29
Christian Weber, Stephanie Gokorsch, and Peter Czermak	

<b>Cell Xpress™-Assisted Analysis of Clone Stability in Recombinant Chinese Hamster Ovary Cells . . . . .</b>	35
Mark A. Gerber, Kimberly A. Lacy, Jennifer Cresswell, Nan Lin, Kevin J. Kayser, and Matthew V. Caple	
<b>An Evaluation of the Intrinsic IgG Production Capabilities of Different Chinese Hamster Ovary Parental Cell Lines . . . . .</b>	41
Genova A. Richardson, Daniel W. Allison, Nan Lin, Matthew V. Caple, and Kevin J. Kayser	
<b>Cell Xpress™ Technology Facilitates High-Producing Chinese Hamster Ovary Cell Line Generation Using Glutamine Synthetase Gene Expression System . . . . .</b>	45
Genova A. Richardson, Nan Lin, Kimberly A. Lacy, Lynn A. Davis, Misa I. Gray, Jennifer Cresswell, Mark A. Gerber, Matthew V. Caple, and Kevin J. Kayser	
<b>CHO-DG44 Cell Line Development by FLP-Targeting – High Level Glycoprotein Expression with Significantly Decreased Time Lines . . . . .</b>	49
Thomas Rose, Anne Furthmann, Marie Etzien, Karsten Winkler, and Volker Sandig	
<b>Transgene Copy Number – Impact on Clone Performance . . . . .</b>	57
Karsten Winkler, Thomas Rose, Anne Furthmann, Christine Paul, Andrea Franke, Rita Berthold, and Volker Sandig	
<b>Single Use Bioreactors: Expressing Protein in Mammalian Cell Suspension . . . . .</b>	63
Kevin A. Auton	
<b>Part II Applied Integrative Physiology</b>	
<b>Gene Modified Hematopoietic Stem Cells for the Treatment of Primary Immunodeficiency Diseases . . . . .</b>	73
M. Grez, S. Stein, U. Siler, and R. Seger	
<b>An Avian Cell Line for Production of Highly Attenuated Viral Vectors .</b>	79
Ingo Jordan, Deborah Horn, Kristin Höwing, and Volker Sandig	
<b>Microelectronic Cellular Vitality Monitoring . . . . .</b>	89
M. Schmidhuber, J. Wiest, A.M. Otto, M. Brischwein, H. Grothe, and B. Wolf	
<b>IFN-<math>\gamma</math> Glycosylation Macroheterogeneity, Energetic Cell Status and Medium Composition During CHO Cell Cultures . . . . .</b>	95
N. Kochanowski, F. Blanchard, R. Cacan, F. Chirat, E. Guedon, A. Marc, and J.-L. Goergen	

<b>Modelling of Neural Metabolism Using <sup>13</sup>C-NMR Spectroscopy and Metabolic Flux Analysis</b> . . . . .	101
Ana P. Teixeira, Sónia Sá Santos, Ana I. Amaral, Nuno Carinhas, Rui Oliveira, Manuel J.T. Carrondo, and Paula M. Alves	
<b>Influence of Glucose and Glutamine Concentration on Metabolism of rCHO Cells</b> . . . . .	107
Hiroshi Matsuoka, Jun-ya Watanabe, and Toshiya Takeda	
<b>Part III Speed and Intensification in Bioprocess Development</b>	
<b>Delivery of Biomolecules with Non-Viral Vectors</b> . . . . .	115
Stéphanie Biri, Fabrice Stock, Abdennaji Adib, and Patrick Erbacher	
<b>Circumventing the “Pay Now or Pay Later” Dilemma: Strategies for Achieving Process Development with Speed and Long-Term Potential</b> . . . . .	121
Carole Heath, Pranhitha Reddy, Martin Allen, Ginny Price, and Victor Fung	
<b>Recombinant Human Antibody Therapeutics: Supply Strategies for Early and Clinical Development from CHO Cells</b> . . . . .	129
Ray Field, Lekan Daramola, Jonathan Dempsey, and Diane Hatton	
<b>Automated Screening of High Producer HEK293F Clones and Analysis of Post-Translational Modifications of Secreted Proteins</b> . . . . .	137
Peter Söhleemann, Claudia Kollert, Jessica Thiems, Elisabeth Casademunt, and Carola Schröder	
<b>Transcriptomic and Proteomic Analysis of Antibody Producing NS0 Cells Cultivated at Different Cell Densities in Perfusion Culture</b> . . . . .	145
Britta Krampe, Halina Swiderek, and Mohamed Al-Rubeai	
<b>New Disposable Fixed-Bed Bioreactor for Cell Culture and Virus Production Based on a Proprietary Agitation and Aeration System</b> . . . . .	151
J. -C. Drugmand, N. Havelange, S. Osumba, F. Bosco, F. Debras, F. Collignon, E. Mathieu, and J. Castillo	
<b>Transcriptomic Analysis of Antibody Producing NS0 Cell Line Under Hypothermic and Hypoxic Conditions</b> . . . . .	157
Halina Swiderek, Anna Logan, and Mohamed Al-Rubeai	
<b>Semi-Continuous Cultures as a Tool for Cell Line Characterization During Process Development</b> . . . . .	161
S. Victores, A. Castillo, E. Faife, Y. Rabasa, Y. Alvarez, L. Rojas, J. Palacio, and A. Figueredo	
<b>Behaviour of GS-CHO Cell Lines in a Selection Strategy</b> . . . . .	165
A. J. Porter, A.J. Dickson, L.M. Barnes, and A.J. Racher	

<b>3D Cultures: Effect on the Hepatocytes Functionality</b> . . . . .	171
Joana Miranda, Manuel J.T. Carrondo, and Paula M. Alves	
<b>Differential Protein Expression Induced by c-Myc Over-Expression: Proteomic Analysis of a CHO Cell Line with Increased Proliferation Capacity</b> . . . . .	177
Darrin Kuystermans and Mohamed Al-Rubeai	
<b>Development of Pilot-Scale Orbital Shake Bioreactors: Ideal for Cost-Effective and Efficient Transient Gene Expression</b> . . . . .	183
Matthieu Stettler, Xiaowei Zhang, Tibor Anderlei, Maria De Jesus, Pascal Lefebvre, David L. Hacker, and Florian M. Wurm	
<b>Helical Tracks in Shaken Cylindrical Bioreactors Improve Oxygen Transfer and Increase Maximum Cell Density Obtainable for Suspension Cultures of Mammalian Cells</b> . . . . .	187
Xiaowei Zhang, Matthieu Stettler, Oscar Reif, Andreas Kocourek, Maria De Jesus, David L. Hacker, and Florian M. Wurm	
<b>Dynamic Optimisation of CHO-IFN<math>\gamma</math> Cell Culture Fed-Batch Time-Profile</b> . . . . .	193
Carolyn M. Lam, Danny C.F. Wong, Miranda G.S. Yap, Efstratios N. Pistikopoulos, and Athanasios Mantalaris	
<b>Long-Term 3D-Culture of HEP G2 Cell Line on Macroporous Ceramic Carriers</b> . . . . .	201
Oscar Platas, Vivien Lutz, Richard Getto, and Ralf Pörtner	
<b>An Integrated Production Process for Human Growth Hormone</b> . . . . .	205
T. Nottorf, H. Büntemeyer, S. Siwiora-Brenke, D. Lütkemeyer, A. Loa, T. Noll, and J. Lehmann	
<b>Efficient Production of Human Monoclonal Antibodies by an Improved Fructose-Based Human Cell Culture</b> . . . . .	209
Yuichi Inoue, Aiko Inoue, and Hiroharu Kawahara	
<b>Coupling Between Cell Kinetics and CFD to Establish Physio-Hydrodynamic Correlations in Various Stirred Culture Systems</b> . . . . .	213
N. Barbouche, E. Olmos, E. Guedon, and A. Marc	
<b>Confocal Microscopy Observation of CHO Cells Cultivated in Presence of Fluorescent – Labelled Rapeseed Peptides</b> . . . . .	219
A. Kastner, C. Frochot, D. Dumas, R. Vanderesse, and A. Marc	
<b>Growth and Production Characteristics of Four Mammalian Cell Lines on a Cost-Effective Serum-Free Medium</b> . . . . .	223
M. Drews and R. Hunt	

<b>A Serum-Free, Transient Transfection System for Enhancing Production of Recombinant Antibodies in Mammalian Cells</b> . . . . .	229
Gaurav Backliwal, Sarah Wulhfard, Fanny Delegrange, Lucia Baldi, Maria deJesus, Florian M. Wurm, and Markus Hildinger	
<b>CFD Study of the Fluid and Particle Dynamics in a Spin-Filter Perfusion Bioreactor</b> . . . . .	233
Alvio Figueredo, Ernesto Chico, Leda R. Castilho, and Ricardo A. Medronho	
<b>High-Yielding CHO Cell Pools for Rapid Production of Recombinant Antibodies</b> . . . . .	239
Diane Hatton, Wyn Forrest-Owen, Greg Dean, Suzanne Gibson, Tori Crook, Amanda Lunney, Steve Ruddock, Alison Davis, Lekan Daramola, and Ray Field	
<b>Increasing Upstream Process Development Efficiency by Implementing Platform Glutamine Synthetase Cell Culture Processes</b> .	245
Robert Heckathorn, Derek Adams, Jeffrey Hunter, and Eric Frieden	
<b>Implementation of High Throughput Systems for Media and Process Development</b> . . . . .	253
Soverin Karmiol, Mykle Gaynor, Robert Kenerson, John Daley, Rich Hassett, Gregory Van Slyke, and Steven Peppers	
<b>Comparison of Cell Culture Methods for Obtaining of rHU-EPO to Large Scale</b> . . . . .	257
E. Ojito, A. Castro, M. Chea, R. Lugo, E. Suárez, A. Medina, M. Arias, and E. Chico	
<b>Optimization and Comparison of Different DNA Methyl Transferase and Histone Deacetylase Inhibitors for Enhancing Transient Protein Expression</b> . . . . .	261
Gaurav Backliwal, Markus Hildinger, Ivan Küttel, David L. Hacker, and Florian M. Wurm	
<b>Proteomic Characterisation of a Glucose-Limited CHO Perfusion Process—Analysis of Metabolic Changes and Increase in Productivity</b> . . . . .	265
Marc Wingens, Jochem Gätgens, Raimund Hoffrogge, and Thomas Noll	
<b>Evaluation of Alternative Signal Sequences</b> . . . . .	271
J. Rance and R. Young	
<b>Process Development for the GMP Production of N-Acetylgalactosamine-6-Sulfate Sulfatase (GALNS) Expressed by CHO Cells</b> . . . . .	275
Cornelia Fux, Christèle Bellon, and Christoph Heinzen	

<b>Improvement of a CHO Fed-Batch Process by Fortifying with Plant Peptones</b> . . . . .	281
Yun Jiang, Erik Svensson, and Véronique Chotteau	
<b><i>O</i>-Glycans on Recombinant MUC1 Produced in CHO K1 Cells Become Less Sialylated with Increased Protein Productivity, as Determined by LC-ESI MS</b> . . . . .	285
Malin Bäckström, Hasse Karlsson, Jochem Gätgens, Thomas Noll, and Gunnar C. Hansson	
<b>A Multiple Minibioreactor Platform for Parallel and Automated Mammalian Cell Culture</b> . . . . .	289
A. Fontova, A. Soley, E. Sarró, J. Gálvez, R. Bragos, J.J. Cairó, and F. Gòdia	
<b>Cultivation of Adherent-Dependent Animal Cells on Microcarriers in a New Disposable Reactor</b> . . . . .	295
N. Havelange, C. Braet, F. Collignon, F. Debras, J.-C. Drugmand, E. Mathieu, S. Vanhamel, and J. Castillo	
<b>CHO Cells Cultivation and Antibodies Production in a New Disposable Bioreactor Based on Magnetic Driven Centrifugal Pump</b> . .	301
F. Collignon, V. Gelbgras, N. Havelange, J.-C. Drugmand, F. Debras, E. Mathieu, V. Halloin, and J. Castillo	
<b>Stability and Productivity of CHO Pools with Respect to Culture Age, Cryopreservation and 20 L Bioreactor Cultivation</b> . . . . .	307
Anders Nelving, Ingrid Svensson, and Mats Lundgren	
<b>In Vitro Disassembly and Reassembly of Triple-Layered Rotavirus-Like Particles</b> . . . . .	313
Maria Candida M. Mellado, Jimmy A. Mena, Manuel J.T. Carrondo, Octavio T. Ramírez, Laura A. Palomares, and Paula M. Alves	
<b>Influence of Culture Conditions on Insect Cell Growth and Protein Production – Comparison of Wave Bioreactor and Shake Flasks</b> . . . . .	319
Mareike Rausch, Jörg Knäblein, Ralf Pörtner, and Petra Helfrich	
<b>Process Intensification Based on Nano-Structured Carbon Carrier Materials and Disposable Devices</b> . . . . .	325
Markus Kürschner and Sohéil Asgari	
<b>Accelerating Fed-Batch Process Development Using Rationally Designed Feed Media</b> . . . . .	331
Scott D. Storms, Jenny Y. Bang, and Tom Fletcher	

<b>Development of a Robust Small-Scale Production Format that Is Predictive of Bioreactor Performance . . . . .</b>	<b>337</b>
Gene W. Lee, D. Troy Richards, Katie Kopycinski, Steve Brennan, Alyssa Handler, and Martin Sinacore	
<b>Biomass Monitoring and CHO Cell Culture Optimization Using Capacitance Spectroscopy . . . . .</b>	<b>343</b>
Rodrigo C.V. Pinto, Paulo A.N. Marinho, Aline B. Oliveira, Geoffrey Esteban, Príamo A. Melo, Ricardo A. Medronho, and Leda R. Castilho	
<b>Characterizing Physiology and Metabolism of High-Density CHO Cell Perfusion Cultures Using 2D-NMR Spectroscopy . . . . .</b>	<b>349</b>
Chetan Goudar, Richard Biener, C. Boisart, Rüdiger Heidemann, Chun Zhang, Albert de Graaf, James Piret, and Konstantin Konstantinov	
<b>BI HEX™ – Platform for Fast Track Generation of High Producer Cell Lines Leading to High-Titer Processes for Production of Therapeutic Proteins from Mammalian Cells . . . . .</b>	<b>359</b>
Torsten W. Schulz, Stefan Schlatter, Hitto Kaufmann, Barbara Enenkel, Helmut Hoffmann, and Stefanos Grammatikos	
<b>Management of Handling, Long-Term Stability and Shipping of Human T-Lymphocytes Bags for Clinical Studies . . . . .</b>	<b>365</b>
I. Giuntini, C. Crosta, L. Romagnoli, M. Galgano, A. Orlandi, S. Castiglioni, S. Trasciatti, L. Cavenaghi, and M.L. Nolli	
<b>Mass Transfer in the CELL-tainer® Disposable Bioreactor . . . . .</b>	<b>371</b>
Nico M.G. Oosterhuis and Pieter van der Heiden	
<b>Efficient Production of Human Monoclonal Antibodies by Combining In Vitro Immunization and Phage Display Methods . . . . .</b>	<b>375</b>
Shinei Matsumoto, Makiko Yamashita, Yeon-suk Jung, Kosuke Tomimatsu, Kiichiro Teruya, Yoshinori Katakura, and Sanetaka Shirahata	
<b>Measurement and Control of Viable Cell Density in a Mammalian Cell Bioprocessing Facility: Validation of the Software . . . . .</b>	<b>379</b>
D. Sergeant, M. Moser, and J.P. Carvell	
<b>Development, Validation, and Application of a Fully Integrated Automation System for Screening and Selection of High Yielding Production Cell Lines . . . . .</b>	<b>385</b>
Tim Gryseels, Lin Zhang, YingPing Zhang, Brian Hossfeld, Heather Jones, Adekunle Onadipe, and John Mott	
<b>Monitoring of Cell Activity: Online Oxygen Uptake Rates in Pulsed Aerated Cell Culture . . . . .</b>	<b>391</b>
A. Bock, Y. Genzel, and U. Reichl	

## Part IV Systems Biotechnology

<b>Metabolite Analysis in Mammalian Cells: How to Generate Reliable Data Sets?</b> . . . . .	397
Joachim B. Ritter, Yvonne Genzel, and Udo Reichl	
<b>Cell-to-Cell Communication for Cell Density-Controlled Bioprocesses</b> .	407
Wilfried Weber and Martin Fussenegger	
<b>Metabolome Analysis in Mammalian Cells: Development and Application of a Sampling Technique</b> . . . . .	413
C. Wiendahl, J.J. Brandner, B. Klein, C. Küppers, B. Luo, S. Ritchie, S. Mazurek, H. Scheefers, T. Noll, U. Schygulla, and M. Oldiges	
<b>Differential Expression Profiling of Industrially Relevant CHO Cell Phenotypes Using a Proprietary CHO-Specific Microarray and Proteomics Technology Platforms</b> . . . . .	421
Mark Melville, Martin S. Sinacore, Dana Di Nino, Kevin McCarthy, Karin Anderson, Kathleen Kopycinski, Gene W. Lee, Steven Max, Patrick Gammell, Padraig Doolan, Paula Meleady, Niall Barron, Mark Leonard, Martin Clynes, and Tim Charlebois	
<b>Towards a Systems-Level Understanding of Increased Specific Productivity in Proliferation Arrested Myeloma NS0 Cells</b> . . . . .	425
Soo Hean Gary Khoo and Mohamed Al-Rubeai	
<b>Proteomic Analysis of Influenza a Virus Infected Mammalian Cells by 2D-DIGE</b> . . . . .	429
D. Vester, E. Rapp, Y. Genzel, D. Gade, and U. Reichl	
<b>Involvement of SRC- and MAP Kinase-Signalings in the Effect of Sericin on Cellular Proliferation and Survival</b> . . . . .	433
Kana Yanagihara, Takuya Saito, Satoshi Takeshita, Masao Miki, Akiko Ogawa, Masahiro Sasaki, Hideyuki Yamada, and Satoshi Terada	
<b>The Unfolded Protein Response and Recombinant Protein Production from In Vitro Cultured Mammalian Cells</b> . . . . .	437
Rosalyn Marchant, Jenny Barker, Peter Klappa, Alan Dickson, and Mark Smales	
<b>A Scalable Process for Helper-Dependent Adenoviral Vector Production Using PEI-Derived Transfection Strategy in Suspension Culture</b> . . . . .	441
E. Dormond, A. Meneses-Acosta, D. Jacob, Y. Durocher, M. Perrier, and A. Kamen	
<b>Functional Analysis of ER Stress Pathway Genes for Apoptosis of NS/0 Cell Line Using RNAi Methods</b> . . . . .	447
Jianguo Yang, Jing Shi, Raghavan Venkat, and Kripa Ram	

<b>Identification of New Protein Substrate Candidates of Transglutaminase in Rat Liver Extracts: Use of 5-(Biotinamido) Pentylamine as a Probe</b> . . . . .	453
Akira Ichikawa, Jin Ishizaki, Manabu Morita, Kentaro Tanaka, and Koji Ikura	
<b>Metabolic Flux Distributions of Adherently Growing MDCK Cells in Different Media</b> . . . . .	459
A. Wahl, Y. Sidorenko, Y. Genzel, and U. Reichl	
<b>Expression of Dermal Extracellular Matrix Proteins in a Newly Developed Full-Thickness Skin Model</b> . . . . .	463
Karsten R. Mewes, Nadja N. Zöller, August Bernd, Alexandra Prießner, Bart DeWever, Rüdiger Graf, and Klaus R. Schröder	
<b>Development of Preparations with Antiviral and Immunostimulatory Effects from Extracts of Green Parts of Coniferous Plants</b> . . . . .	469
E. Nechaeva, N. Varaksin, T. Ryabicheva, T. Ilcheva, T. Sen'kina, R. Martynyuk, and A. Vilesov	
<b>Serum-Free Transfection of CHO Cells with Chemically Defined Transfection Systems to Generate Transient and Stable Cell Lines</b> . . .	475
Reisinger Hannes, Vorauer-Uhl Karola, Steinfeldner Willibald, Wagner Andreas, Katinger Hermann, and Kunert Renate	
<b>“Glycomics”: Development and Characterization of Glycan-Based Biotechnological Products</b> . . . . .	479
Matthias Kaup, Véronique Blanchard, Detlef Grunow, Stefan Risch, Silke Langhammer, Werner Reutter, Rudolf Tauber, and Markus Berger	
<b>Development of a Cell-Culture-Based Platform for Viral Vaccine Production</b> . . . . .	481
G. Forno, C. Paillet, R. Kratje, and M. Etcheverrigaray	
<b>Screening of Natural Compounds Affecting Type I Interferon Signalling</b>	485
M. Bollati-Fogolín, M. Oggero, S. Mirazo, R. Frank, R. Kratje, and W. Müller	
<b>Part V Competing and Complementary Approaches to Animal Cell Technologies</b>	
<b>Therapeutic Proteins from Transgenic Cows' Milk</b> . . . . .	491
J.A. Bercovich, C.A. Melo, and M.E. Criscuolo	
<b>Development of Edible Plant Vaccines</b> . . . . .	497
Heike Mikschofsky, Patricia König, Günther Keil, Horst Schirrneier, and Inge Broer	

<b>Human Cell Lines for Production of Biopharmaceuticals</b> . . . . .	503
Gudrun Schiedner, Nikos Gaitatzis, Sabine Hertel, Corinna Bialek, Helmut Kewes, Christoph Volpers, and Gero Waschütza	
<b>Concentration and Purification of Densonucleosis Virus by Tangential Membrane Filtration and by Ion Exchange Membranes</b> . . .	513
Peter Czermak, David L. Grzenia, Anne Wolf, Jonathan O. Carlson, Rachel Specht, Binbing Han, and S. Ranil Wickramasinghe	
<b>Effect of ManNAc and its Derivatives on Glycosylation to Proteins Produced by Mammalian Cell Culture</b> . . . . .	517
Kaori Doi, Megumi Hayashi, Ichiro Ebata, Shinya Yamaguchi, Yasuhiro Ohta, and Satoshi Terada	
<b>Purification of a Chimeric Simian – Human Immunodeficiency Virus-Like Nanoparticle from HEK293 Cell Culture</b> . . . . .	521
Luísa Pedro and Guilherme N. M. Ferreira	
<b>Effects of Plant Peptones Supplemented Medium on CHO Cells</b> . . . . .	529
Barbau Jérémie, Michiels Jean-François, De Boel Sébastien, Spiros N. Agathos, and Schneider Yves-Jacques	
<b>Synthetic Low Density Lipoprotein a Novel Biomimetic Lipid Supplement for Serum Free Tissue Culture</b> . . . . .	533
G.W. Halbert, G. Duncan, and S. Hayavi	
<b>Part VI Solutions and Applications</b>	
<b>Scale-Down Approach for Animal-Free Polio Vaccine Production</b> . . . . .	541
Wilfried A.M. Bakker, Yvonne E. Thomassen, and Leo A. van der Pol	
<b>“Novel Scaffolds for Tissue Engineering – Nano-Structured Surfaces Promote Selective Cell Attachment and Cell Differentiation”</b> .	551
Sohéil Asgari and Markus Kürschner	
<b>Unconventional Experimental Concepts Enabling High Speed High Performance Media/Process Development</b> . . . . .	559
Martin Jordan, Damien Voisard, Nadia Bencherif, Antoine Berthoud, Laetitia Tercier, Beate Kleuser, and Gianni Baer	
<b>A Study on Bioscaffolds of Polysialic Acid and <math>\beta</math>-Glucan for Cell Culture and Tissue Engineering Applications</b> . . . . .	567
Yvonne Stark, Stephanie Bruns, Bastian Rode, Silke Berski, Gerald Dräger, Frank Stahl, Cornelia Kasper, Andreas Kirschning, and Thomas Scheper	
<b>A Preliminary Study on Spider Silk as Biomaterial for Peripheral Nerve Regeneration</b> . . . . .	573
Stephanie Bruns, Yvonne Stark, Dana Marten, Christina Allmeling, Cornelia Kasper, Frank Stahl, and Thomas Scheper	

<b>Investigation of the Effect of Mechanical Strain on the Osteogenic Differentiation of Mesenchymal Stem Cells . . . . .</b>	579
Solvig Diederichs, Daniel Riechers, Friederike Sempf, Susanne Kall, Cornelia Kasper, Martijn van Griensven, and Thomas Scheper	
<b>Biofunctional Polymer-Mineral Composites as Scaffolds for Bone Tissue Engineering . . . . .</b>	591
Stefanie Röker, Solvig Diederichs, Victor Korzhikov, Thomas Scheper, Tatiana Tennikova, and Cornelia Kasper	
<b>New Water-Soluble Polymers for Construction of Biofunctionalized Scaffolds for Bone Tissue Engineering: Synthesis and Adsorption Study . . . . .</b>	599
V. Korzhikov, E. Vlakh, S. Diederichs, S. Roeker, T. Tennikova, and C. Kasper	
<b>Selection of High-Producing Cells Via Cell Sorting Using an Affinity Matrix . . . . .</b>	607
Larissa Behr, Pierre Moretti, Fabienne Anton, Cornelia Kasper, and Thomas Scheper	
<b>The Effects of Medium Supplement on High-Level Production of Recombinant Human Factor IX in CHO Cell . . . . .</b>	613
InHwan Lim, Jung-Seob Kim, Guehwa Lee, Murim Choi, and Yeup Yoon	
<b>Case Study Large Scale Cell Culture Facility . . . . .</b>	619
Dirk Steinhäuser	
<b>Glycosylation of Influenza A Virus Hemagglutinin . . . . .</b>	621
J. Schwarzer, E. Rapp, and U. Reichl	
<b>Production of Retroviral Pseudotype Vectors in Fixed Bed Reactors for Use in Gene Therapy . . . . .</b>	625
Dirk Nehring, Ralf Pörtner, and Peter Czermak	
<b>Swellscreen – Rapid Baculovirus Titration Method in Microplate Format . . . . .</b>	629
Eva Lindskog, Thomas Falkman, and Elke Lüllau	
<b>Comparing Vero and MDCK Cells for Influenza A Virus Production in Microcarrier Systems . . . . .</b>	635
Y. Genzel, C. Dietzsch, and U. Reichl	
<b>Expansion of Human Articular Chondrocytes on Microcarriers Enhances the Production of Cartilage Specific Matrix Components . . . . .</b>	639
Christiane Goepfert, Vivien Lutz, Svenja Lünse, Sabrina Kittel, Katharina Wiegandt, Michael Kammal, Klaus Püschel, and Ralf Pörtner	

<b>Automated Cell Culture Handling – Characteristics and Procedures . . .</b>	<b>645</b>
Stephanie Mathes, Roland Durner, Uwe Müller, and Ursula Graf-Hausner	
<b>Bioreactor Satellite Culture Experiments in the Start-Up of a Cell Culture Technical Support Lab . . . . .</b>	<b>647</b>
Jean-Philippe Goisnard, Leopold Berteau, Thibaud Stoll, and Patrick Salou	
<b>Advantages of Hydrodynamic Cell Separation in Industrial Cell Culture Processes . . . . .</b>	<b>657</b>
Bernd Schröder, Elsayed Ahmed Elsayed, Johanna Olowonia, and Roland Wagner	
<b>Optimization and Characterization of the Process for Large Volume Cell Banking in Bags . . . . .</b>	<b>665</b>
S. Lünse, Rüdiger Heidemann, and Chun Zhang	
<b>Development of Screening Method for IgA-Promoting Factors Derived from Food Extracts Using a Human Myeloma Cell Line . . . . .</b>	<b>669</b>
Kouhei Mizuno, Yusuke Tanii, Yuichi Inoue, Aiko Inoue, and Hiroharu Kawahara	
<b>Cryopreservative Solution Using Sericin . . . . .</b>	<b>675</b>
Kenji Ikeda, Yoko Oumi, Akiko Ogawa, Masahiro Sasaki, Hideyuki Yamada, and Satoshi Terada	
<b>Fructan as a Novel Effective Factor for Mammalian Cell Culture . . . . .</b>	<b>679</b>
Hideharu Higashiya, Kyoichi Kobayashi, and Satoshi Terada	
<b>Online Determination of Oxygen Uptake and Carbon Dioxide Production Rates in Mammalian Cell Culture Using Mass Spectrometry . . . . .</b>	<b>683</b>
J. Haas, T. Tröbs, C. Clemens, M. Wunder, M. Rüger, and T.W. Schulz	
<b>Optimisation of mAb Concentration in Microcarrier Based Perfusion Compared to Batch/Fed-Batch Cultivation . . . . .</b>	<b>689</b>
Christian Kaisermayer and Gerald Blüml	
<b>Characterization of the Novel Human AGE1hn Cell Line for Production of Recombinant Proteins . . . . .</b>	<b>693</b>
S. Northoff, H. Büntemeyer, V. Sandig, S. Zietze, and T. Noll	
<b>Rapid Selection of Optimal Formulations for Divergent Clones Through Screening Chinese Hamster Ovary Media Library . . . . .</b>	<b>699</b>
Avril A. Lawshé, Min Zhang, Ashley Smith, Wade Nudson, James S. Ross, and Matthew V. Caple	
<b>Development of a Vaccine Candidate Against Heartwater . . . . .</b>	<b>703</b>
I. Marcelino, M.F.Q. Sousa, C. Peixoto, A.I. Amaral, N. Vachieri, T. Lefrançois, D. Martinez, M.J.T. Carrondo, and P.M. Alves	

<b>Animal Component Free T-Cell Culture . . . . .</b>	<b>711</b>
W.G. Whitford, B.B. Barnett, and J.H. Manwaring	
<b>Characterization of Cholesterol-Independent GS-NS/0 Recombinant Antibody Cell Lines . . . . .</b>	<b>717</b>
Jianguo Yang, Jing Shi, Raghavan Venkat, and Kripa Ram	
<b>Development of a Fed-Batch Process for the Production of a Recombinant Protein X in CHO-GS System – Case Study from the Cell to Reactor Process Ready for Pilot Scale Cultivation . . . . .</b>	<b>723</b>
Véronique Chotteau, Yun Jiang, Jeannette Westin, Kerstin Dahlenborg, Anna Sjöblom-Hallén, Erik Svensson, and Michael Öberg	
<b>Scaffolds for Articular Joint Tissue Engineering . . . . .</b>	<b>727</b>
A. Pla, E. Sarró, M. Caminal, D. Peris, L. Vidal, J.J. Cairó, and F. Gòdia	
<b>Effect of Tunisian Aromatic Plant Extracts on Melanogenesis . . . . .</b>	<b>735</b>
Kyoko Matsuyama, Mitsuko Kawano, Mohamed Elyes Kchouk, Hiroshi Shinmoto, and Hiroko Isoda	
<b>Effects of Capsaicin on Energy Metabolism by Human Intestinal Epithelial Cell Line Caco-2 . . . . .</b>	<b>739</b>
Junkyu Han and Hiroko Isoda	
<b>Human A1AT Production – Propagating a Newly Developed Human Cell Line in a Novel Disposable Perfusion Bioreactor . . . . .</b>	<b>743</b>
Silke Langhammer, Ralf Pörtner, Volker Sandig, Genadii Suchich, Sascha Tonevitzky, Markus Berger, Veronique Blanchard, Matthias Kaup, Vanessa Frenz, Rudolf Tauber, René Brecht, Susann Koch, and Uwe Marx	
<b>Characterization of Diffusion and Flow Relations in the Novel Membrane Based Perfusion Bioreactor . . . . .</b>	<b>749</b>
Silke Langhammer, Anke Wellmann, Richard Ammer, Thomas Linz, Rudolf Tauber, Ralf Pörtner, and Uwe Marx	
<b>Protective Effect of Di-O-Caffeoylquinic Acid on Human-Derived Neurotypic SH-SY5Y Cells Against Alzheimer’s Disease Amyloid-Beta-Induced Toxicity . . . . .</b>	<b>755</b>
Hiroko Isoda, Junkyu Han, and Hideyuki Shigemori	
<b>Flow Through Ceramic Foams – A Future Cell Culture Challenge . . . . .</b>	<b>759</b>
V. Goralczyk, A. Bischof, A. Berthold, L. Blessing, H. Schubert, and R. King	
<b>Measles Virus Production in MRC-5 Cells Grown on Microcarriers in a Stirred Bioreactor . . . . .</b>	<b>765</b>
Khaled Trabelsi, Semy Majoul, Fatma Charfi, and Héla Kallel	

**A New System for the Enrichment of Cell Subclones Secreting High Levels of IgG Using Magnetic Cell Sorting (MACS® Technology)** . . . . . 771  
 Alexandra S.H. Hoch, Kerstin Zörner, Stefanie Kattenbach, Mayke Busch, Erik Schneider, Iris Bürger, and Ulf Bethke

**Soy Hydrolysate Optimization for Cell Culture Applications** . . . . . 777  
 Jeanette N. Hartshorn, Sandra McNorton, Chas Hernandez, Ed van der Ent, and Matthew V. Caple

**The Effect of Bioreactor pH and Temperature on Protein Glycosylation in Perfusion Cultures of Mammalian Cells** . . . . . 785  
 Eva Sajan, Ricaredo Matanguihan, Rüdiger Heidemann, Susan Abu-Absi, Wilfred Asuncion, Glenn Yamasaki, Xue Wu, Jianmin Chen, John E. Murphy, and Chun Zhang

**Evaluation of Cell Growth Characteristics on Chitosan-Alginate Membranes to Assess Their Potential Application on Highly Exuding Skin Lesions and In Vivo Evaluation in Wounded Cat** . . . . . 789  
 Ana Paula Rodrigues, Selma C. Genari, Neusa M. Paulo, Maria da Conceição, Marcelo S. de Brito e Silva, and Ângela Maria Moraes

**Vaccine Production Utilizing the Potential of Microcarriers in Disposable Bioreactor** . . . . . 795  
 J.E. Schouwenberg, T. Van der Velden-de Groot, and G. Blueml

**Characterization of an Anti-Idiotypic Antibody Blocking the Capacity of the HIV-1 Specific nMAb 2F5** . . . . . 803  
 Johannes Gach, Willibald Steinfeldner, Martina Löschel, Rainer Hahn, Heribert Quendler, Hermann Katinger, and Renate Kunert

**Cultivation of PER.C6® Cells in the Novel CELL-Tainer™ High-Performance Disposable Bioreactor** . . . . . 807  
 G. M. Zijlstra and N. Oosterhuis

**Scale-Up of a PER.C6® Fed-Batch Process in 50 and 250 L Hyclone Single Use Bioreactors Compared to 50 and 250 L Stainless Steel Bioreactors** . . . . . 809  
 G. M. Zijlstra

**Capacitance Sensor as a Robust Tool for Cell Culture Monitoring in Process Development and Manufacturing** . . . . . 811  
 Damien Voisard, Geoffrey Esteban, and Gianni Baer

**Effect of Different Cell Culture Medium Surfactants on Cell Growth and Viability** . . . . . 819  
 Kristina Martinelle, Annika Mattsson, Brita Rippner-Blomqvist, and Elisabeth Lindner

<b>Conventional Stirred Bioreactor Control System for Monitoring and Controlling pH and DO in a Wave Bioreactor . . . . .</b>	<b>823</b>
Peter Aizawa, Charlotte Benemar, Cecilia Wingenblixt, Kristina Martinelle, and Elisabeth Lindner	
<b>On-Line Monitoring of Vero Cells Cultures During the Growth and Rabies Virus Process Using Biomass Spectrometer . . . . .</b>	<b>829</b>
Samia Rourou, Stéphanie Gaumon, and Héla Kallel	
<b>Inducing of Human IgE Antibodies by In Vitro Immunization . . . . .</b>	<b>833</b>
Shuichi Hashizume and Hiroharu Kawahara	
<b>Oxygen Uptake Rate (OUR) Estimation in High Density Mammalian Cell Perfusion Cultures . . . . .</b>	<b>837</b>
C. Cruz, K. Joeris, C. Goudar, C. Zhang, and K. Konstantinov	
<b>Use of Yeast Derived Nutrients for Cell Culture in Serum-Free Media . . . . .</b>	<b>843</b>
I. Chevalot, C. Dziukala, E. Olmos, I. Marc, D. Druaux-Borreill, E. Oriol, and A. Marc	
<b>A Novel Approach to the Production of Plant-Derived Hydrolysates Yields Medium Supplements with Enhanced Performance in Cell Culture Systems . . . . .</b>	<b>847</b>
James F. Babcock, Debra A. Merrill, and Shawn R. Smith	
<b>Monitoring the Cell Size Distribution of Mammalian Cell Cultures Using On-Line Capacitance Measurements . . . . .</b>	<b>853</b>
Sven Ansoerge, Olivier Henry, Marc Aucoin, Robert Voyer, John P. Carvell, and Amine Kamen	
<b>Biosimilarity of Recombinant Human EPO Products from CHO Cell Lines: A Carbohydrate Structural View . . . . .</b>	<b>861</b>
Nicolas Grammel, Frank Dittrich, Sebastian Kandzia, Eckart Grabenhorst, and Harald S. Conradt	
<b>Quantitative N-Glycan Mapping of Glycoprotein Therapeutics by HPAEC-PAD: Glycosylation Characteristics of Different Recombinant Human EPO Products . . . . .</b>	<b>867</b>
Sebastian Kandzia, Nicolas Grammel, Eckart Grabenhorst, and Harald S. Conradt	

# Contributors

**Susan Abu-Absi** Bayer HealthCare, Pharmaceuticals, Global Biological Development, Cell Culture Development, 800 Dwight Way, Berkeley, CA 94710, USA

**M. Adam** Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

**Derek Adams** Fermentation and Cell Culture Development Group, Alexion Pharmaceuticals, Inc., Cheshire, CT, USA

**Abdennaji Adib** Polyplus-Transfection S.A., Bioparc, Boulevard Sébastien Brant, BP 90018, 67401 Illkirch, France

**D. Aibibu** Rheinisch-Westfälische Technische Hochschule Aachen, Germany

**Peter Aizawa** Octapharma AB, SE-11275 Stockholm, Sweden, peter.aizawa@octapharma.se

**Martin Allen** Process and Analytical Sciences, Amgen Inc., Seattle, WA, USA

**Daniel W. Allison** Cell Sciences and Development, SAFC Biosciences, 2909 Laclede Ave, Saint Louis, MO 63103, USA, dan.allison@sial.com

**Christina Allmeling** Medizinische Hochschule Hannover, Klinik für Plastische-, Hand- und Wiederherstellungschirurgie, Podbielskistr. 380, D-30659 Hannover, Germany, allmeling.christina@mh-hannover.de

**Mohamed Al-Rubeai** School of Chemical and Bioprocess Engineering and Centre for Synthesis and Chemical Biology (CSCB), University College Dublin, Belfield, Dublin 4, Ireland

**Paula M. Alves** IBET/ITQB (Instituto de Biologia Experimental e Tecnológica/Instituto de Tecnologia Química e Biológica), Oeiras, Portugal, marques@itqb.unl.pt

**Y. Alvarez** Center of Molecular Immunology (CIM), P.O. Box 16040, Havana City 11600, Cuba

**Ana I. Amaral** IBET/ITQB (Instituto de Biologia Experimental e Tecnológica/Instituto de Tecnologia Química e Biológica), Oeiras, Portugal

**Richard Ammer** ProBioGen AG, Berlin, Germany

**Tibor Anderlei** Adolf Kühner AG, 4127 Birsfelden, Switzerland

**Karin Anderson** Cell and Molecular Sciences, Wyeth BioPharma, Andover, MA, USA

**Wagner Andreas** Polymun Scientific, Immunbiologische Forschung GmbH, Nussdorfer Lände 11, A-1190 Vienna, Austria

**Sven Ansorge** Institut de Recherche en Biotechnologie, CNRC, 6100 Avenue Royalmount, Montréal, Québec H4P 2R2, Canada; École Polytechnique de Montréal, C.P. 6079, succ. Centre-ville, Montréal, Québec H3C 3A7, Canada

**Fabienne Anton** Institut für Technische Chemie, Universität Hannover, Callinstraße 3, 30167 Hannover, Germany

**M. Arias** Center of Molecular Immunology, Havana, Cuba

**Eddy Arnoldussen** Phytovation B.V., Wassenaarseweg 72, 2333 AL Leiden, The Netherlands

**Sohéil Asgari** Cinvention AG, Rheingastr. 190-196, D-65203 Wiesbaden, Germany, s.asgari@cinvention.com

**Wilfred Asuncion** Bayer HealthCare, Pharmaceuticals, Global Biological Development, Cell Culture Development, 800 Dwight Way, Berkeley, CA 94710, USA

**Marc Aucoin** Institut de Recherche en Biotechnologie, CNRC, 6100 Avenue Royalmount, Montréal, Québec H4P 2R2, Canada

**Kevin A. Auton** Cellexus Limited, 12 Ramsay Court, Hinchingsbrooke Business Park, Huntingdon, Cambridgeshire, PE29 6FY United Kingdom, kevin.auton@cellexusbiosystems.com

**G. Backliwal** Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

**Malin Bäckström** Department of Medical Biochemistry/Mammalian Protein Expression core facility, Göteborg University, Box 440, 405 30 Göteborg, Sweden, malin.backstrom@medkem.gu.se

**Gianni Baer** Merck Serono S.A., Z.I.B, 1809 Fenil-sur-Corsier, Switzerland

**James F. Babcock** Sheffield Pharma Ingredients, Division of Kerry Bio-Science, 158 State Highway 320, Norwich, NY 13815, USA

**Wilfried A.M. Bakker** Netherlands Vaccine Institute (NVI), Process Development department, P.O. Box 457, 3720 AL Bilthoven, The Netherlands, wilfried.bakker@nvi-vaccin.nl

**Lucia Baldi** Ecole Polytechnique Fédérale de Lausanne (EPFL), Laboratory of Cellular Biotechnology, Lausanne, Switzerland

**Jenny Y. Bang** Irvine Scientific, Santa Ana, CA, USA

**N. Barbouche** CNRS-INPL, Laboratoire des Sciences du Génie Chimique UPR 6811, 2, av. de la Forêt de Haye – BP 172 – 54505, Vandœuvre-les-Nancy Cedex, France

**Jenny Barker** Protein Science Group, Department of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK

**L.M. Barnes** The Michael Smith Building, The University of Manchester, Oxford Road, Manchester, M13 9PT, UK

**B.B. Barnett** Thermo Fisher Scientific, Logan, UT, USA

**Niall Barron** National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

**Christoph L. Bausch** Cell Sciences and Development, SAFC Biosciences, 2909 Laclede Ave, Saint Louis, MO 63103, USA, christoph.Bausch@sial.com

**Larissa Behr** Institut für Technische Chemie, Universität Hannover, Callinstrasse 3, 30167 Hannover, Germany

**Christèle Bellon** Inotech Labor AG, Eulerstrasse 55, CH-4051 Basel, Switzerland

**Nadia Bencherif** Merck Serono S.A., CH-1809 Fenil-sur-Corsier, Switzerland

**Charlotte Benemar** Octapharma AB, SE-11275 Stockholm, Sweden

**J.A. Bercovich** Bio Sidus S.A., Constitución 4234 (C1254ABX), Buenos Aires, Argentina, cmelo@biosidus.com.ar

**Markus Berger** Institute of Clinical Chemistry and Pathobiochemistry, Charité Platz 1, 10117 Berlin, Germany, markus.berger@charite.de

**August Bernd** Department of Dermatology and Venerology, University Hospital, Frankfurt/Main, Germany

**Silke Berski** Leibniz Universität Hannover, Institut für Organische Chemie, D-30167 Hannover, Germany

**A. Berthold** Department of Ceramic Materials, Technische Universitaet Berlin, Germany

**Antoine Berthoud** Merck Serono S.A., CH-1809 Fenil-sur-Corsier, Switzerland

**Rita Berthold** ProBioGen AG, Berlin, Germany

**Leopold Berteau** BioPharmaceutical Operations (BPO) Manufacturing Huningue, Centre de Biotechnologie, Novartis Pharma S.A.S., 8, rue de l'Industrie, B.P. 355, F-68333 Huningue Cedex, France

**Ulf Bethke** Miltenyi Biotec GmbH, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany

**Corinna Bialek** CEVEC Pharmaceuticals GmbH, Gottfried-Hagen-Str. 62, 51105 Köln, Germany

**Richard Biener** University of Applied Sciences Esslingen, Department of Natural Sciences, Kanalstrasse 33, 73728 Esslingen, Germany

**Stéphanie Biri** Polyplus-Transfection S.A., Bioparc, Boulevard Sébastien Brant, BP 90018, 67401 Illkirch, France

**A. Bischof** Engineering Design and Methodology, Technische Universitaet Berlin, Germany

**F. Blanchard** Laboratoire des Sciences du Génie Chimique, UPR CNRS 6811, ENSAIA-INPL – 2, avenue de la Forêt de Haye, 54 505 Vandoeuvre-lès-Nancy, France

**Véronique Blanchard** Institute of Clinical Chemistry and Pathobiochemistry, Charité Platz 1, 10117 Berlin, Germany

**L. Blessing** Engineering Design and Methodology, Technische Universitaet Berlin, Germany

**Gerald Blüml** GE Healthcare, Vienna, Austria

**G. Blueml** GE Healthcare, Uppsala, Sweden

**A. Bock** Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany, bock@mpi-magdeburg.mpg.de

**C. Boisart** METabolic EXplorer SA, Biopole Clermont-Limagne, F-63360 St. Beauzire, France

**M. Bollati-Fogolin** Cell Biology Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay; Laboratorios de Cultivos Celulares, Universidad Nacional del Litoral, Santa Fe, Argentina, mbollati@pasteur.edu.uy

**Trissa Borgschulte** Cell Sciences and Development, SAFC Biosciences, Saint Louis, MO 63103, USA, tborgschulte@sial.com

**F. Bosco** Artelis SA, Rue de Ransbeek 310, 1120 Brussels, Belgium

**C. Braet** ATMI LifeSciences, Hoegaarden, Belgium

**R. Bragos** Departament d'Enginyeria Electrònica, Universitat Politècnica de Catalunya, Barcelona, Spain

**J.J. Brandner** Institute for Micro Process Engineering IMVT, Research Center Karlsruhe, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany

**René Brecht** ProBioGen AG, Berlin, Germany

**Steve Brennan** Wyeth BioPharma, Andover, MA, USA

**M. Brischwein** Technical University of Munich, Arcisstr. 21, D-80333 Munich, Germany

**Inge Broer** Agrobiotechnologie, Universität Rostock, Justus-von-Liebig-Weg 8, 18059 Rostock, Germany, Inge.Broer@uni-rostock.de

**Stephanie Bruns** Leibniz Universität Hannover; Institut für Technische Chemie, D-30167 Hannover, Germany

**H. Büntemeyer** Institute of Cell Culture Technology, University of Bielefeld, Bielefeld, Germany

**Iris Bürger** Miltenyi Biotec GmbH, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany

**Mayke Busch** Miltenyi Biotec GmbH, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany

**R. Cacan** Unité de Glycobiologie Structurale et Fonctionnelle, UMR CNRS 8576, 59655 Villeneuve d'Ascq, France

**J.J. Cairó** Departament d' Enginyeria Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

**M. Caminal** Grup d'Enginyeria Cellular i Tissular, Departament d'Enginyeria Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

**Matthew V. Caple** Cell Sciences and Development, SAFC Biosciences, 2909 Laclede Ave, Saint Louis, MO 63103, USA, matt.caple@sial.com

**Nuno Carinhas** IBET/ITQB (Instituto de Biologia Experimental e Tecnológica/Instituto de Tecnologia Química e Biológica), Oeiras, Portugal

**Jonathan O. Carlson** Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA

**Manuel J.T. Carrondo** IBET/ITQB (Instituto de Biologia Experimental e Tecnológica/Instituto de Tecnologia Química e Biológica), Oeiras, Portugal; FCT/UNL (Faculdade de Ciências e Tecnologia/Universidade Nova Lisboa), Monte da Caparica, Portugal

**John P. Carvell** Aber Instruments Ltd, Aberystwyth, UK, jc@aberinstruments.com

**Elisabeth Casademunt** Octapharma Biopharmaceuticals GmbH, Am Klopferspitz 19/19a, 82152 Martinsried, Germany, casademunt@octagene.com

**S. Castiglioni** Areta International S.r.l., Via R. Lepetit 34, 21040 Gerenzano, VA, Italy

**Leda R. Castilho** Federal University of Rio de Janeiro, COPPE, PEQ, Cell Culture Engineering Laboratory (LECC), Caixa Postal 68502, 21941-972 Rio de Janeiro/RJ, Brazil, leda@peq.coppe.ufrj.br

- A. Castillo** Center of Molecular Immunology (CIM), P.O. Box 16040, Havana City 11600, Cuba
- J. Castillo** Artelis SA, Rue de Ransbeek 310, 1120 Brussels, Belgium
- A. Castro** Center of Molecular Immunology, Havana, Cuba
- L. Cavenaghi** Areta International S.r.l., Via R. Lepetit 34, 21040 Gerenzano, VA, Italy
- Fatma Charfi** Viral Vaccines Research and Development Unit, Institut Pasteur de Tunis, 13, place Pasteur, BP.74, 1002 Tunis, Tunisia
- Tim Charlebois** Cell and Molecular Sciences, Wyeth BioPharma, Andover, MA, USA
- M. Chea** Center of Molecular Immunology, Havana, Cuba
- Jianmin Chen** Bayer HealthCare, Pharmaceuticals, Global Biological Development, Expression Technology, Berkeley, CA 94710, USA
- I. Chevalot** Laboratoire des Sciences du Génie Chimique, UPR CNRS 6811, ENSAIA-INPL – 2, avenue de la Forêt de Haye, 54 505 Vandoeuvre-lès-Nancy, France, Isabelle.Chevalot@ensaia.inpl-nancy.fr
- F. Chirat** Unité de Glycobiologie Structurale et Fonctionnelle, UMR CNRS 8576, 59655 Villeneuve d'Ascq, France
- Murim Choi** Mogam Biotechnology Research Institute, Yongin, Gyonggi-Do 446-799, Republic of Korea
- Véronique Chotteau** Biovitrum, Biopharmaceutical Process Development, Process Sciences Stockholm and Göteborg, Sweden, veronique.chotteau@biovitrum.com
- C. Clemens** Department of Biopharmaceutical Process Science, Upstream Development, Cell Culture Technology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, christoph.clemens@bc.boehringer-ingenelheim.com
- Martin Clynes** National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- F. Collignon** Artelis SA, Rue de Ransbeek 310, 1120 Brussels, Belgium, j.drugmand@artelis.be
- Maria da Conceição** School of Veterinary, Federal University of Goiás, Goiânia, SP, Brazil
- Harald S. Conradt** GlycoThera GmbH, 38124 Braunschweig, Germany
- Jennifer Cresswell** Cell Sciences and Development, SAFC Biosciences, Saint Louis, MO, USA

**M.E. Criscuolo** Bio Sidus S.A., Constitución 4234 (C1254ABX), Buenos Aires, Argentina

**Tori Crook** Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

**C. Crosta** Areta International S.r.l., Via R. Lepetit 34, 21040 Gerezano, VA, Italy

**C. Cruz** Global Biologics Development, Bayer HealthCare, Berkeley, CA 94710, USA

**Peter Czermak** Institute of Biopharmaceutical Technology, University of Applied Sciences Wiesentrasse 14, 35390, Giessen, Germany; Department of Chemical Engineering, Kansas State University, Manhattan KS, USA, peter.czermak@tg.fh-giessen.de

**Kerstin Dahlenborg** Biovitrum, Biopharmaceutical Process Development, Process Sciences, Stockholm and Göteborg, Sweden

**John Daley** Invitrogen Corporation, 3175 Staley Road, Grand Island, New York 14072, USA

**Lekan Daramola** Cambridge Antibody Technology, Granta Park, Cambridge, CB21 6GH, UK

**Alison Davis** Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

**Lynn A. Davis** Cell Sciences and Development, SAFC Biosciences, 13804 W. 107th Street, Lenexa, KS 66215, USA

**Greg Dean** Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

**F. Debras** Artelis SA, Rue de Ransbeek 310, 1120 Brussels, Belgium

**Maria De Jesus** ExcellGene SA, 1870 Monthey, Switzerland

**Fanny Delegrange** Laboratory of Cellular Biotechnology, EPFL SV IBI LBTC, CH B41 424 (bâtiment CH), Station 6, CH-1015 Lausanne, Switzerland, fanny.delegrange@epfl.ch

**Jonathan Dempsey** Cambridge Antibody Technology, Granta Park, Cambridge, CB21 6GH, UK; Invitrogen, 3 Fountain Drive, Inchinnan, PA4 9RF, UK

**Bart DeWever** Phenion GmbH & Co. KG, Düsseldorf, Germany

**A.J. Dickson** The Michael Smith Building, The University of Manchester, Oxford Road, Manchester, M13 9PT, UK

**Solvig Diederichs** Institut für Technische Chemie, Universität Hannover, Callinstraße 3, 30167 Hannover, Germany, Diederichs@iftc.uni-hannover.de

**C. Dietzsch** Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering group, Sandtorstr. 1, 39106 Magdeburg, Germany; Lehrstuhl für Bioverfahrenstechnik, Technical University Dresden, Dresden, Germany

**Frank Dittrich** GlycoThera GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany, grammel@glycothera.de

**Kaori Doi** Department of Applied Chemistry and Biotechnology, University of Fukui, 3-9-1 Bunkyo, Fukui 910-8507, Japan, fkrht810@yahoo.co.jp

**Padraig Doolan** National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

**E. Dormond** Animal Cell Technology Group, Biotechnology Research Institute, National Research Council Canada, 100 Royalmount Avenue, Montréal, Québec, H4P 2R2 Canada; Chemical Engineering Department, Ecole Polytechnique de Montréal, Campus de l'Université de Montréal, 2500, chemin de Polytechnique, Montréal, Québec, H3T 1J4 Canada

**Gerald Dräger** Leibniz Universität Hannover, Institut für Organische Chemie, D-30167 Hannover, Germany

**M. Drews** Tallinn University of Technology and Competence Centre for Cancer Research, Akadeemia tee 15, 12618, Tallinn, Estonia, monika.drews@vtak.ee

**D. Druaux-Borreill** BIOSPRINGER, 103 rue Jean Jaurès-94701, Maisons-Alfort cedex, France

**J.-C. Drugmand** Artelis SA, Rue de Ransbeek 310, 1120 Brussels, Belgium, j.drugmand@artelis.be

**D. Dumas** Laboratoire d'Énergétique et de Mécanique Théorique et Appliquée, UMR 7563, CNRS-INPL, Nancy-Université, Nancy, France

**G. Duncan** Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow, G4 0NR, UK

**Roland Durner** Tecan AG, Männedorf, Switzerland

**Y. Durocher** Animal Cell Technology Group, Biotechnology Research Institute, National Research Council Canada, 100 Royalmount Avenue, Montréal, Québec, H4P 2R2 Canada

**C. Dziukala** Laboratoire des Sciences du Génie Chimique, UPR CNRS 6811, ENSAIA-INPL – 2, avenue de la Forêt de Haye, 54 505 Vandoeuvre-lès-Nancy, France

**Ichiro Ebata** Marukin Bio Inc., 27 Monnomae, Todo, Uji, Kyoto 611-0013, Japan

**Elsayed Ahmed Elsayed** National Research Centre, Cairo, Egypt

**Barbara Enenkel** Department of Biopharmaceutical Process Science, Upstream Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

**Alfred Engel** Roche Diagnostics GmbH, Nonnenwald 2, D-82372 Penzberg, Germany

**Eva-Maria Engelhardt** Ecole Polytechnique Fédérale de Lausanne, Switzerland, Engelhardt.E@gmx.de

**Ed van der Ent** DMV International, Delhi, NY 13753, USA

**Patrick Erbacher** Polyplus-Transfection S.A., Bioparc, Boulevard Sébastien Brant, BP 90018, 67401 Illkirch, France, perbacher@polyplus-transfection.com

**Geoffrey Esteban** FOGALE Nanotech, Nîmes, France

**M. Etcheverrigaray** Laboratorio de Cultivos Celulares. Facultad de Bioquímica y Ciencias, Biológicas. UNL. C.C. 242, Ciudad Universitaria (S3000ZAA) Santa Fe, Pcia, Santa Fe, Argentina

**Marie Etzien** ProBioGen AG, Berlin, Germany

**E. Faife** Center of Molecular Immunology (CIM), P.O. Box 16040, Havana City 11600, Cuba

**Thomas Falkman** Protein Science and Supply, DECS, AstraZeneca R&D Södertälje, Building 841, S-151 85 Södertälje, Sweden

**Guilherme N.M. Ferreira** IBB – Institute for Biotechnology and Bioengineering, Centre for Molecular and Structural Biomedicine, Universidade do Algarve, Faro, Portugal, gferrei@ualg.pt

**Ray Field** Cambridge Antibody Technology, Granta Park, Cambridge, CB21 6GH, UK, liz.browne@cambridgeantibody.com

**A. Figueredo** Center of Molecular Immunology, Calle 15 esq. 216, Havana, Cuba, alvio@cim.sld.cu

**Tom Fletcher** Irvine Scientific, Santa Ana, CA, USA

**A. Fontova** Departament d'Enginyeria Electrònica, Universitat Politècnica de Catalunya, Barcelona, Spain

**Wyn Forrest-Owen** Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

**G. Forno** Zelltek S.A., Biológicas. UNL. C.C. 242, Ciudad Universitaria (S3000ZAA) Santa Fe, Pcia, Santa Fe, Argentina, gforno@zelltek.com.ar

**R. Frank** Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany

**Andrea Franke** ProBioGen AG, Berlin, Germany

**Vanessa Frenz** Charité Universitätsmedizin, Berlin, Germany

**Eric Frieden** Fermentation and Cell Culture Development Group, Alexion Pharmaceuticals, Inc., Cheshire, CT, USA

**C. Frochot** DCPR, UMR 7630, CNRS-INPL, Nancy-Université, Nancy, France

**Victor Fung** Process and Analytical Sciences, Amgen Inc., Seattle, WA, USA

**Martin Fussenegger** Institute for Chemical and Bioengineering, ETH Zurich, 8093 Zurich, Switzerland, fussenegger@chem.ethz.ch

**Anne Furthmann** ProBioGen AG, Berlin, Germany

**Cornelia Fux** Inotech Labor AG, Eulerstrasse 55, CH-4051 Basel, Switzerland, fux@inotech.ch

**Johannes Gach** Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, A-1190 Vienna, Austria, hannes.reisinger@boku.ac.at

**D. Gade** Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstraße 1, 39106 Magdeburg, Germany

**Nikos Gaitatzis** CEVEC Pharmaceuticals GmbH, Gottfried-Hagen-Str. 62, 51105 Köln, Germany

**M. Galgano** Areta International S.r.l., Via R. Lepetit 34, 21040 Gerenzano, VA, Italy

**J. Gálvez** Departament d' Enginyeria Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

**Patrick Gammell** National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

**Jochem Gätgens** Cell Culture/Fermentation Group, Institute for Biotechnology 2, Research Center Jülich, 52425 Jülich

**Stéphanie Gaumon** FOGALE Nanotech, 25 rue de l'Hostellerie, Ville Active, 30 900 Nîmes, France

**Mykle Gaynor** Invitrogen Corporation, 3175 Staley Road, Grand Island, New York 14072, USA

**V. Gelbgras** Chemical Engineering, Applied Sciences Faculty, ULB, Brussels, Belgium

**Selma C. Genari** UNIPINHAL – Centro Regional Universitário Espírito Santo do Pinhal, SP, Brazil

**Yvonne Genzel** Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering group, Sandtorstr. 1, 39106 Magdeburg, Germany, genzel@mpi-magdeburg.mpg.de

**Mark A. Gerber** Cell Sciences and Development, SAFC Biosciences, Saint Louis, MO, USA, mark.gerber@sial.com

**Richard Getto** Hamburg University of Technology, Institute of Bioprocess and Biosystems Engineering, Denickestr. 15, D-21071 Hamburg, Germany

**Suzanne Gibson** Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB21 6GH, UK

**I. Giuntini** Areta International S.r.l., Via R. Lepetit 34, 21040 Gerenzano, VA, Italy, mlnolli@aretaint.com

**F. Gòdia** Departament d' Enginyeria Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

**Christiane Goepfert** Hamburg University of Technology, Institute of Bioprocess and Biosystems Engineering, Denickestr. 15, D-21071 Hamburg, Germany

**J.-L. Goergen** Laboratoire des Sciences du Génie Chimique, UPR CNRS 6811, ENSAIA-INPL – 2, avenue de la Forêt de Haye, 54 505 Vandoeuvre-lès-Nancy, France, Jean-Louis.Goergen@ensaia.inpl-nancy.fr

**Jean-Philippe Goisnard** BioPharmaceutical Operations (BPO) Manufacturing Huningue, Centre de Biotechnologie, Novartis Pharma S.A.S., 8, rue de l'Industrie, B.P. 355, F-68333 Huningue Cedex, France

**Stephanie Gokorsch** Institute of Biopharmaceutical Technology, University of Applied Sciences Giessen-Friedberg, Giessen, Germany

**V. Goralczyk** Department of Measurement and Control, Technische Universitaet Berlin, Germany

**Chetan Goudar** Bayer Healthcare, Biological Products Division, 800 Dwight Way, Berkeley, CA 94710, USA

**Albert de Graaf** METabolic EXplorer SA, Biopole Clermont-Limagne, F-63360 St. Beuzire, France

**Rüdiger Graf** Phenion GmbH & Co. KG, Düsseldorf, Germany

**Ursula Graf-Hausner** Zurich University of Applied Sciences, Winterthur, Switzerland

**Eckart Grabenhorst** GlycoThera GmbH, 38124 Braunschweig, Germany

**Stefanos Grammatikos** Department of Biopharmaceutical Process Science, Upstream Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

**Nicolas Grammel** GlycoThera GmbH, 38124 Braunschweig, Germany, grammel@glycothera.de

**Misa I. Gray** Cell Sciences and Development, SAFC Biosciences, 13804 W. 107th Street, Lenexa, KS 66215, USA

**M. Grez** Georg-Speyer-Haus, Frankfurt, Germany, grez@em.uni-frankfurt.de

**Martijn van Griensven** Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Donaueschingenstraße 13, A-1200 Vienna, Austria

**H. Grothe** Technical University of Munich, Arcisstr. 21, D-80333 Munich, Germany

**Detlef Grunow** Institute of Clinical Chemistry and Pathobiochemistry, Charité Platz 1, 10117 Berlin, Germany

**Tim Gryseels** Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO 63017, USA, timothy.d.gryseels@pfizer.com

**David L. Grzenia** Institute of Biopharmaceutical Technology, University of Applied Sciences, Wiesenstrasse 14, 35390 Giessen, Germany; Department of Chemical Engineering, Colorado State University, Fort Collins, CO, USA

**E. Guedon** Laboratoire des Sciences du Génie Chimique, UPR CNRS 6811, ENSAIA-INPL – 2, avenue de la Forêt de Haye, 54 505 Vandoeuvre-lès-Nancy, France

**Peter de Haan** Phytovation B.V., Wassenaarseweg 72, 2333 AL Leiden, The Netherlands, peter.dehaan@phytovation.com

**J. Haas** Department of Biopharmaceutical Process Science, Upstream Development, Cell Culture Technology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

**David L. Hacker** Laboratory of Cellular Biotechnology, EPFL SV IBI LBTC, CH B41 424 (bâtiment CH), Station 6, CH-1015 Lausanne, Switzerland, david.hacker@epfl.com

**Rainer Hahn** Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, A-1190 Vienna, Austria

**G.W. Halbert** Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow, G4 0NR, UK, g.w.halbert@strath.ac.uk

**V. Halloin** Chemical Engineering, Applied Sciences Faculty, ULB, Brussels, Belgium

**Binbing Han** Department of Chemical Engineering, Colorado State University, Fort Collins, CO, USA

**Junkyu Han** Graduate School of Life and Environmental Sciences, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8572, Japan

**Alyssa Handler** Wyeth BioPharma, Andover, MA, USA